Type-1B angiotensin II receptor
Description:
| Description |
|---|
|
Drug Relations:
|
angiotensin II
|
Angiotensin II is a naturally occurring peptide hormone of the renin-angiotensin-aldosterone system (RAAS) that causes vasoconstriction and an increase in blood pressure. Angiotensin II raises blood pressure by vasoconstriction and increased aldosterone release. Direct action of angiotensin II on the vessel wall is mediated by binding to the G-protein-coupled angiotensin II receptor type 1 on vascular smooth muscle cells, which stimulates Ca2+/calmodulin-dependent phosphorylation of myosin and causes smooth muscle contraction. | Bioactivity details | MOA |
|
|
eprosartan
|
angiotensin II receptor antagonist; structure given in first source | Bioactivity details | MOA |
|
|
irbesartan
|
A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease. | Bioactivity details | MOA |
|
|
losartan
|
An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II. | Bioactivity details | MOA |
|
|
saralasin
|
An octapeptide analog of angiotensin II (bovine) with amino acids 1 and 8 replaced with sarcosine and alanine, respectively. It is a highly specific competitive inhibitor of angiotensin II that is used in the diagnosis of HYPERTENSION. | Bioactivity details | MOA |
|
|
tasosartan
|
angiotensin II antagonist; structure given in first source | Bioactivity details | MOA |
|
|
telmisartan
|
A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION. | Bioactivity details | MOA |
|
|
valsartan
|
A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION. It has been approved in combination with sacubitril (under the name ENTRESTO) for the treatment of heart failure. | Bioactivity details | MOA |
|